v3.26.3
Collaboration Agreements - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended 45 Months Ended
Jan. 27, 2023
Dec. 13, 2022
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Dec. 31, 2023
Sep. 30, 2026
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Deferred revenue, net of current portion     $ 12,338   $ 12,338   $ 7,798   $ 12,338
Shares issued under equity agreement   10,683,761              
Investment, Type [Extensible Enumeration]   G S K Equity Investment [Member]              
Purchase price per share   $ 4.68              
Collaboration revenue recognized     13,158 $ 7,608 53,676 $ 25,482      
Collaboration and license agreement, deferred revenue current     9,111   9,111   44,440   9,111
GSK Collaboration Agreement [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront payment under collaboration agreement $ 120,000 $ 120,000              
Collaboration Agreement in Premium   $ 15,400              
Deferred revenue, net of current portion     12,300   12,300   7,800   12,300
Aggregate initiation payment         32,000        
Milestone payment     12,000   12,000   10,000 $ 20,000  
Collaboration revenue recognized     13,200 $ 7,600 53,700 $ 25,500     199,700
Recognition of remaining deferred revenue         35,900        
Contract with Customer, Liability, Total     21,400   21,400   52,200   21,400
Collaboration and license agreement, deferred revenue current     $ 9,100   $ 9,100   $ 44,400   $ 9,100